The newly added medicines include two for type 2 diabetes, Jentadueto and Jentadueto XR, and one for chronic obstructive ...
AURA Phase 2 clinical trial designed to evaluate the safety and efficacy of AP02 compared to placebo in patients with ...
Patients with COPD and heart failure treated with SGLT-2 inhibitors experienced higher rates of volume depletion and adverse renal events. Chronic obstructive pulmonary disease (COPD) reduces the ...
Chronic obstructive pulmonary disease, or COPD, is the 5th-leading cause of death in the United States and the cause of more ...
Escalating to extrafine single-inhaler triple therapy significantly reduces exacerbations in patients with moderate to severe COPD.
The tool is the most accurate prognostic score of its kind and has the potential to improve COPD patient care whilst easing pressure on the NHS.
New long-acting muscarinic antagonist-long-acting beta agonist users had a decreased risk for a first moderate/severe COPD ...
Findings provide early evidence supporting potential disease-modifying activity of AP01 (inhaled pirfenidone) in patients ...
With receipt of inhaled treprostinil for 52 weeks, adults with idiopathic pulmonary fibrosis had less FVC decline compared ...
GSK is sourcing early-stage science across a wide range of technologies and disease areas, while placing more selective bets ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis. The study met its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results